Business
Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium
NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology
About this update from Rain Enhancement Technologies Holdco, Inc.
NEWARK, Calif. , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain . Abstract Title: Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53 Poster Session: Molecular Targeted Agents 1 Presenter: Vijaya G. Tirunagaru , Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics , Newark, CA Poster Session Date: Wednesday, October 26, 2022 Location: Exhibition Hall A copy of the presentation materials can be accessed by visiting the " Resources ” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website. About Rain Therapeutics Inc. Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. Media Contact Jordyn Temperato LifeSci Communications [email protected] Investor Contact Bob Yedid LifeSci Advisors +1.646.597.6989 [email protected] Source: Rain Therapeutics Inc
View stock analysis, news, and events for Rain Enhancement Technologies Holdco, Inc.